- Bristol Myers Squibb (BMY, Financial) reported Q1 2025 revenues of $11.2 billion, a 6% decrease compared to 2024.
- Growth Portfolio revenues increased by 16%, driven by strong performance of Opdivo and Breyanzi.
- Non-GAAP EPS guidance for 2025 has been increased to $6.70-$7.00 per share.
Bristol Myers Squibb (BMY) has announced its financial results for the first quarter of 2025, reporting total revenues of $11.2 billion. This represents a 6% decrease, or 4% in constant currency terms, compared to the same quarter in 2024. U.S. revenues dropped by 7% to $7.9 billion, while international revenues saw a slight decrease of 2% to $3.3 billion.
The company’s Growth Portfolio, which includes key products like Opdivo and Breyanzi, showed robust performance with revenues climbing by 16% to $5.6 billion. In contrast, the Legacy Portfolio experienced a decline, with revenues dropping by 20%, mainly due to generic competition affecting products like Revlimid.
Bristol Myers Squibb also raised its full-year revenue guidance to a range of $45.8 billion to $46.8 billion. The non-GAAP earnings per share (EPS) guidance has been increased to between $6.70 and $7.00, underscoring the company’s confidence in its strategic initiatives and product pipeline advancements.
CEO Christopher Boerner emphasized that the company remains committed to delivering transformational medicines through disciplined execution and innovation in its product development pipeline.
